CL2021002374A1 - Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg) - Google Patents

Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg)

Info

Publication number
CL2021002374A1
CL2021002374A1 CL2021002374A CL2021002374A CL2021002374A1 CL 2021002374 A1 CL2021002374 A1 CL 2021002374A1 CL 2021002374 A CL2021002374 A CL 2021002374A CL 2021002374 A CL2021002374 A CL 2021002374A CL 2021002374 A1 CL2021002374 A1 CL 2021002374A1
Authority
CL
Chile
Prior art keywords
egcg
fibroids
vitamin
treatment
agent
Prior art date
Application number
CL2021002374A
Other languages
English (en)
Inventor
Vittorio Unfer
Original Assignee
Lo Li Pharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lo Li Pharma Srl filed Critical Lo Li Pharma Srl
Publication of CL2021002374A1 publication Critical patent/CL2021002374A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de vitamina D y un agente seleccionado del grupo que consiste en: galato de epigalocatequina (EGCG), catequina, galocatequina y galato de epicatequina (ECG), para la prevención, control y/o tratamiento de fibromas en un sujeto.
CL2021002374A 2019-03-15 2021-09-10 Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg) CL2021002374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000003843A IT201900003843A1 (it) 2019-03-15 2019-03-15 Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)

Publications (1)

Publication Number Publication Date
CL2021002374A1 true CL2021002374A1 (es) 2022-04-18

Family

ID=66690890

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002374A CL2021002374A1 (es) 2019-03-15 2021-09-10 Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg)

Country Status (25)

Country Link
US (1) US20220160734A1 (es)
EP (1) EP3937927B1 (es)
KR (1) KR20210139390A (es)
CN (1) CN113573706A (es)
AR (1) AR118372A1 (es)
BR (1) BR112021018308A2 (es)
CA (1) CA3130592A1 (es)
CL (1) CL2021002374A1 (es)
CO (1) CO2021011789A2 (es)
EA (1) EA202192524A1 (es)
ES (1) ES2981336T3 (es)
GE (1) GEP20247615B (es)
HR (1) HRP20240970T1 (es)
HU (1) HUE067061T2 (es)
IT (1) IT201900003843A1 (es)
JO (1) JOP20210222A1 (es)
MA (1) MA55281A (es)
MX (1) MX2021010491A (es)
PE (1) PE20220130A1 (es)
PL (1) PL3937927T3 (es)
RS (1) RS65682B1 (es)
SG (1) SG11202108937VA (es)
UA (1) UA127910C2 (es)
UY (1) UY38608A (es)
WO (1) WO2020187729A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200011114A1 (it) * 2022-05-26 2023-11-26 Recordati Ind Chimica E Farmaceutica S P A “uso dell’associazione tadalafil e vitamina d3 per la preparazione di un prodotto per il trattamento orale della ipertrofia prostatica benigna e relativi metodi produttivi”

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US6039967A (en) 1997-04-03 2000-03-21 Point Biomedical Corporation Intravesical drug delivery system
US20050032741A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin Compositions
RU2366447C2 (ru) * 2003-10-09 2009-09-10 Медигене Аг Лекарственное средство для лечения предраковых поражений кожи
US8221803B1 (en) * 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
CN102670584A (zh) * 2011-03-18 2012-09-19 江苏凯吉生物科技有限公司 没食子儿茶素没食子酸酯在制备抗良性前列腺增生药物中的应用
CN105029406A (zh) * 2015-04-14 2015-11-11 劲膳美生物科技股份有限公司 子宫肌瘤医学配方食品
CN107708678A (zh) * 2015-04-14 2018-02-16 阿托萨遗传学公司 治疗乳房病症以及雌激素相关病症的组合物和方法
CN104856996B (zh) * 2015-04-27 2018-01-05 南京舒鹏生物科技有限公司 吡咯喹啉醌、其衍生物和/或盐新的药用用途以及药用组合物
CN105054025B (zh) * 2015-08-09 2017-11-14 青岛大学附属医院 一种用于炎症性肠病患者的低脂低渗低渣型肠内营养粉剂
WO2017132775A1 (en) * 2016-02-05 2017-08-10 Viteava Pharmaceuticals Inc. Novel compositions and methods for the treatment of leiomyoma
WO2023099763A1 (en) * 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer

Also Published As

Publication number Publication date
AR118372A1 (es) 2021-09-29
KR20210139390A (ko) 2021-11-22
CO2021011789A2 (es) 2021-09-20
PE20220130A1 (es) 2022-01-27
UA127910C2 (uk) 2024-02-07
GEP20247615B (en) 2024-03-25
CA3130592A1 (en) 2020-09-24
UY38608A (es) 2020-10-30
EA202192524A1 (ru) 2021-11-19
HUE067061T2 (hu) 2024-09-28
EP3937927C0 (en) 2024-04-17
JOP20210222A1 (ar) 2023-01-30
BR112021018308A2 (pt) 2021-11-23
WO2020187729A1 (en) 2020-09-24
IT201900003843A1 (it) 2020-09-15
PL3937927T3 (pl) 2024-09-02
ES2981336T3 (es) 2024-10-08
EP3937927B1 (en) 2024-04-17
SG11202108937VA (en) 2021-09-29
US20220160734A1 (en) 2022-05-26
CN113573706A (zh) 2021-10-29
HRP20240970T1 (hr) 2024-10-25
EP3937927A1 (en) 2022-01-19
MA55281A (fr) 2022-01-19
MX2021010491A (es) 2021-10-01
RS65682B1 (sr) 2024-07-31

Similar Documents

Publication Publication Date Title
MX2017011884A (es) Composiciones cosmeticas topicas contra radicales libres.
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
WO2016176279A8 (en) Uses of cannabidiol for treatment of infantile spasms
NZ716858A (en) Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
BR112015007131A2 (pt) métodos para melhorar o efeito de egcg em atenuar a perda muscular esquelética
BR112017026025A2 (pt) composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
BR112017006113A2 (pt) combinações sinérgicas de auristatina
BR112018016729A2 (pt) novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase
MX2021012268A (es) Composicion autoemulsionante de farmacos polifenolicos flavonoides, metodo de preparacion de la misma, composicion farmaceutica de la misma y aplicacion de la misma.
BR112016002524A2 (pt) alvos moleculares para a prevenção e/ou tratamento de fibrose, cicatrizes hipertróficas e quelóides
CL2021002374A1 (es) Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg)
AR119043A1 (es) Métodos para acelerar la cicatrización mediante el uso de composiciones cannabinoides
BR112022002289A2 (pt) Composições de curativo líquido e seus usos veterinários
MX2020006443A (es) Combinacion de un retinoide y un extracto de silybum marianum (l.) gaertn.
MX2018005028A (es) Composicion para el cuidado de la piel y metodos para la misma.
EP3747453A4 (en) <SMALLCAPS /> AUCUBA COMPOSITION FOR THE PREVENTION OR TREATMENT OF DRY EYES WITH <NS1: I> JAPONICA </ NS1: I> EXTRACT
CR20120236A (es) Formulación líquida de control de plagas
BRPI1100012A2 (pt) agente para realçar a expressão de fatores associados com redox
GB2566235A (en) A novel formulation for rapid wound healing and control of infection
BR112018011021A2 (pt) método para inativar xenoantígenos em tecidos biológicos
IN2015KN00370A (es)
MY197721A (en) Composition and uses thereof
BR112019000711A2 (pt) xibornol como um agente virucida para uso no tratamento profilático ou terapêutico de uma infecção causada por um ou mais vírus e composto farmacêutico virucida
NZ732032A (en) Compositions comprising l-theanine, proanthocyanidin(s) and a catechin and uses thereof